AroCell AB (publ) announced today that the patent no 6715770 and titled “Monoclonal anti-TK1 antibodies” is granted by the Japanese Patent Office.
The patent application relates to AroCell’s proprietary monoclonal antibodies used for determining the Thymidine kinase 1 concentration in serum samples. These antibodies are used in the AroCell TK 210 ELISA kit.
“We are delighted that this patent has been granted by the Japanese Patent Office. This reinforces our patent position and increases AroCell’s attractiveness as a business partner in Asia.” says Michael Brobjer, CEO AroCell.